TACE联合靶向、免疫治疗在BCLCB/C期肝细胞癌中的 应用

Application of TACE combined with molecular targeted therapy and immunotherapy in BCLC B/C hepatocellularcarcinoma

经动脉化疗栓塞(TACE)是巴塞罗那临床肝癌(BCLC)分期系统B期肝细胞癌(HCC)的标准治疗方法。但TACE存在一定的局限性,TACE联合系统治疗或许更能使BCLCB/C期HCC患者获益。探索TACE分别联合靶向治疗、免疫治疗及靶向+免疫治疗BCLCB/C期HCC的疗效及安全性,将为HCC的临床治疗提供新的思路。

Transcatheter arterial chemoembolization(TACE)is the standard treatment for Barcelona Clinic Liver Cancer(BCLC)stage B hepatocellular carcinoma(HCC).However,TACE has some limitations,TACE combined with systemic therapy may be more beneficial to patients with BCLC stage B/C HCC.To explore the efficacy and safety of TACE combined with molecular targeted therapy,immunotherapy and molecular targeted therapy+immunotherapy in the treatment of B/C stage HCC of BCLC will provide new ideas for the clinical treatment of HCC.